Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of telitacicept for lupus nephritis
CTR20223334Phase 2Active
- Sponsor
- RemeGen
- Start
- Apr 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by RemeGen. Started Apr 2023; status: active.
02
Drugs
telitacicept
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20223334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223334.